Business
Jupiter Neurosciences to Participate in NobleCon21
Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondrial dysfunction, today announced that its management team will present at the upcoming Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, in Boca Raton, FL.Held annually in South Florida, NobleCon brings...
About this update from Jupiter Neurosciences, Inc.
[{"type":"text","content":"Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic platform targeting neuroinflammation and mitochondrial dysfunction, today announced that its management team will present at the upcoming Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, in Boca Raton, FL.","length":453,"tagName":"p"},{"type":"text","content":"Held annually in South Florida, NobleCon brings together public company executives, institutional investors, family offices, and industry leaders for a high-impact, in-person experience.","length":186,"tagName":"p"},{"type":"text","content":"Management will be available during the event for one-on-one meetings with the investment community. To schedule a meeting, please contact your NobleCon representative or Jupiter Neurosciences' investor relations by emailing [email protected].","length":246,"tagName":"p"},{"type":"text","content":"NobleCon21 is the premier forum for emerging growth companies, investor access, and networking, designed to maximize visibility and engagement for small and mid-cap companies through presentations, qualified one-on-one investor meetings and receptions.","length":252,"tagName":"p"},{"type":"text","content":"About Jupiter Neurosciences, Inc.","length":33,"tagName":"p"},{"type":"text","content":"Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be ...